Literature DB >> 25059737

Vitiligo: what's new in the psycho-neuro-endocrine-immune connection and related treatments.

Torello Lotti1, Matteo Zanardelli, Angelo Massimiliano D'Erme.   

Abstract

Vitiligo is an acquired depigmentary skin disorder of unknown origin characterized by well-demarcated, white macules of varying size and distribution. Despite relevant new research and progresses, why melanocytes disappear to induce the characteristic achromic lesions of vitiligo is not fully understood. In spite of recent findings implicating genetic, immune and oxidative stress factors, the exact pathogenesis of vitiligo remains obscure. An innovative concept based on a functional cross-talk between the nervous and immune system is emerging. Neuropeptides released from peripheral nerve endings could synergize with new cytokines to adversely affect melanocyte function and viability. Evidence is increasing regarding the role of neuropeptides in the pathogenesis of vitiligo and a new winning approach to vitiligo therapy based on neuropeptides regulation is at the horizon.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25059737     DOI: 10.1007/s10354-014-0288-7

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  41 in total

Review 1.  Autoimmune aspects of vitiligo.

Authors:  E H Kemp; E A Waterman; A P Weetman
Journal:  Autoimmunity       Date:  2001       Impact factor: 2.815

2.  Substance P may play a part during depigmentation in vitiligo. A pilot study.

Authors:  R Falabella; M I Barona; I C Echeverri; A Alzate
Journal:  J Eur Acad Dermatol Venereol       Date:  2003-05       Impact factor: 6.166

3.  Psychoneuroimmunology and dermatology.

Authors:  E M Farber
Journal:  Int J Dermatol       Date:  1993-02       Impact factor: 2.736

4.  Classification of vitiligo: a challenging endeavor.

Authors:  Jana Hercogová; Robert A Schwartz; Torello M Lotti
Journal:  Dermatol Ther       Date:  2012 Nov-Dec       Impact factor: 2.851

5.  Guidelines for the management of vitiligo: the European Dermatology Forum consensus.

Authors:  A Taieb; A Alomar; M Böhm; M L Dell'anna; A De Pase; V Eleftheriadou; K Ezzedine; Y Gauthier; D J Gawkrodger; T Jouary; G Leone; S Moretti; L Nieuweboer-Krobotova; M J Olsson; D Parsad; T Passeron; A Tanew; W van der Veen; N van Geel; M Whitton; A Wolkerstorfer; M Picardo
Journal:  Br J Dermatol       Date:  2012-11-02       Impact factor: 9.302

Review 6.  Neuronal control of skin function: the skin as a neuroimmunoendocrine organ.

Authors:  Dirk Roosterman; Tobias Goerge; Stefan W Schneider; Nigel W Bunnett; Martin Steinhoff
Journal:  Physiol Rev       Date:  2006-10       Impact factor: 37.312

Review 7.  Neuropeptides in skin.

Authors:  T Lotti; G Hautmann; E Panconesi
Journal:  J Am Acad Dermatol       Date:  1995-09       Impact factor: 11.527

Review 8.  Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors.

Authors:  A Slominski; J Wortsman; A Pisarchik; B Zbytek; E A Linton; J E Mazurkiewicz; E T Wei
Journal:  FASEB J       Date:  2001-08       Impact factor: 5.191

Review 9.  The psychological aspects of vitiligo.

Authors:  Matthew Silvan
Journal:  Cutis       Date:  2004-03

10.  Gene expression analysis of melanocortin system in vitiligo.

Authors:  Külli Kingo; Eerik Aunin; Maire Karelson; Mari-Anne Philips; Ranno Rätsep; Helgi Silm; Eero Vasar; Ursel Soomets; Sulev Kõks
Journal:  J Dermatol Sci       Date:  2007-07-25       Impact factor: 4.563

View more
  8 in total

1.  TRPV2 POLYMORPHISMS INCREASE OR REDUCE THE RISK OF TYPE 2 DIABETES - HASHIMOTO THYROIDITIS COMORBIDITY.

Authors:  F Bulut Arikan; F A Özdemir; D Şen; S Erdem; S Yörübulut; H Doğan; L Keskin
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jan-Mar       Impact factor: 0.877

2.  Identifying Patients at Higher Risk of Depression Among Patients with Vitiligo at Outpatient Setting.

Authors:  Mana Abdullah Alharbi
Journal:  Mater Sociomed       Date:  2020-06

3.  Associations between serum levels of brain-derived neurotrophic factor, corticotropin releasing hormone and mental distress in vitiligo patients.

Authors:  Assiya Kussainova; Laura Kassym; Almira Akhmetova; Eugenia Dvoryankova; Natalya Glushkova; Zaituna Khismetova; Saltanat Adilgozhina; Raikhan Tuleutayeva; Alida Kaskabayeva; Meruyert Massabayeva; Laura Pak; Yuliya Semenova
Journal:  Sci Rep       Date:  2022-05-04       Impact factor: 4.996

Review 4.  Skin-Nerve Co-Culture Systems for Disease Modeling and Drug Discovery.

Authors:  Stacey C Schutte; Feni Kadakia; Steve Davidson
Journal:  Tissue Eng Part C Methods       Date:  2021-02-02       Impact factor: 3.056

5.  An Isoxazole Chalcone Derivative Enhances Melanogenesis in B16 Melanoma Cells via the Akt/GSK3β/β-Catenin Signaling Pathways.

Authors:  Li Yin; Chao Niu; Li-Xin Liao; Jun Dou; Maidina Habasi; Haji Akber Aisa
Journal:  Molecules       Date:  2017-11-28       Impact factor: 4.411

Review 6.  The Promising Role of Chemokines in Vitiligo: From Oxidative Stress to the Autoimmune Response.

Authors:  Shan He; Jinhua Xu; Jinfeng Wu
Journal:  Oxid Med Cell Longev       Date:  2022-01-19       Impact factor: 6.543

7.  Study of Novel Furocoumarin Derivatives on Anti-Vitiligo Activity, Molecular Docking and Mechanism of Action.

Authors:  Chao Niu; Deng Zang; Haji Akber Aisa
Journal:  Int J Mol Sci       Date:  2022-07-19       Impact factor: 6.208

8.  A Network Pharmacology Approach to Uncover the Molecular Mechanisms of Herbal Formula Kang-Bai-Ling for Treatment of Vitiligo.

Authors:  Manyuan Xu; Jianxin Shi; Zhongsheng Min; Hongliu Zhu; Weiguo Sun
Journal:  Evid Based Complement Alternat Med       Date:  2019-11-03       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.